BRAIN Biotech AG
Alexander Pelzer has a diverse work experience in the field of research and development. Alexander started as a Research Associate at Heinrich-Heine-Universität Düsseldorf in 2010. Alexander then worked as an Intern at AB Enzymes in 2012. In 2014, they joined Forschungszentrum Jülich as a PHD Student and later became a Postdoc. In 2014, they also started working at BRAIN Biotech AG as a Project Manager, leading various internal and external collaboration projects. Alexander subsequently held roles as the Techplatform Head Tailor-made Biocatalysts and Unit Head Enzymes & Biocatalysts at BRAIN Biotech AG. Currently, they hold the position of VP, Head of Research and Development at the same company. Overall, their work experience includes enzyme discovery and production, optimization of expression hosts, enzyme characterization, and protein engineering.
Alexander Pelzer attended the University of Düsseldorf from 2005 to 2009, where they obtained a Diplom degree in the field of Biology.
This person is not in any offices
BRAIN Biotech AG
BRAIN Biotech AG is a leading European supplier of biobased products and solutions such as enzymes and proteins, microbial production strains, natural compounds and biotechnological solutions for more sustainable industrial processes. We focus on the fields of nutrition, health and environment. BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. The Group's business activities are divided into the segments BioProducts, BioScience and BioIncubator. The BioProducts segment comprises the product business with specialty enzymes and other proteins, for which the Group operates fermentation facilities in the United Kingdom and production facilities in continental Europe and the United States. The BioScience segment offers research-intensive custom solutions based on enzyme technology, strain development, bioprocess development and natural product screening. The BioIncubator segment conducts its own R&D projects or those initiated with partners with high value-added potential. A particularly promising incubator project is the development of the Company's own CRISPR-based gene editing technology platform, which is currently being established and expanded.